Vaxxinity Collaboration an Important Step Forward for Vaccine Development for Neurodegenerative Diseases

31 January 2024

New York, January 31, 2024 - PRISM MarketView - In encouraging news for those living with neurodegenerative diseases, Vaxxinity, Inc. (Nasdaq: VAXX) has entered into a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.

The research is funded by a grant from the state of Florida and will support the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases. Neurodegenerative disease affects approximately 50 million Americans each year according to the National Institutes of Health (NIH).

Our collaboration with the University of Florida will support the continued development of vaccines for neurodegenerative diseases affecting millions of people worldwide. Our work with UF will drive a deeper understanding of how to neutralize toxic proteins in the brain implicated in diseases such as Alzheimer’s and Parkinson’s."

Mei Mei Hu, CEO of Vaxxinity

“This work builds upon years of research on our synthetic peptide technology platform to target endogenous proteins, and can help us to develop better candidates for neurodegenerative diseases in the future. We are not afraid to tackle the biggest challenges in science, and this collaboration is an important way we are advancing our vision to provide cheaper, safer, more convenient, and effective medicines for chronic disease to all.”

Mei Mei Hu, CEO of Vaxxinity

Highlights

Researchers at UF will conduct a series of preclinical studies to explore the effects of Vaxxinity’s candidates for neurodegenerative disease on relevant biological targets, such as beta-amyloid, tau, and alpha-synuclein, in various in vitro and in vivo studies, including models of disease and antibody-target binding assays.

Vaxxinity has previously shown immunogenicity, target engagement, and efficacy in preclinical animal models of multiple neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.

Vaxxinity’s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets.

About Vaxxinity

Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.

PRISM MarketView does not provide investment advice.

Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com

To see this content properly accept cookies.

PRISM MarketView Social Media

To see this content properly accept cookies.